Stem cell therapy in chronic ischemic heart dysfunction with and without viability.
A growing number of clinical trials are evaluating the effects of stem cell therapy in patients with chronic ischemic heart dysfunction. As most of the clinical trials included a limited and different number of patients, various stem cell sources and several delivery approaches, results vary substantially between these studies. We analyse whether the assessment of myocardial viability may be important when evaluating effects of stem cell transplantation on parameters of left ventricular remodeling. Viability assessment could help to find the best type of stem cell and the best method of cell delivery to be used in chronic ischemic heart dysfunction.
Sánchez
Pedro L
PL
Cardiology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Sanz-Ruiz
Ricardo
R
Fernández-Santos
M Eugenia
ME
Villa
Adolfo
A
Gutiérrez
Enrique
E
Fernández
Lucia
L
Vázquez
Sandra
S
Lorenzo
M José
MJ
Fernández-Avilés
Francisco
F
D002470:Cell Survival / Q000502:physiology; D002908:Chronic Disease; D006333:Heart Failure / Q000473:pathology* / Q000601:surgery*; D006801:Humans; D017202:Myocardial Ischemia / Q000473:pathology* / Q000601:surgery*; D033581:Stem Cell Transplantation / Q000379:methods*; D013234:Stem Cells / Q000473:pathology; D016896:Treatment Outcome; D020257:Ventricular Remodeling